

Performance in Delivery Q3 2017-2018

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
26310	13/LO/1517	131080	A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of FG-4592 in the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis	Number Agreed	5	5	Date Agreed	15/07/2017	0	31/03/2017	0	Withdrawn By Sponsor	6 patients consented but failed randomisation due to the inclusion criteria
26311	14/NE/1169	163225	Phase IV Trial Assessing the ImPact of Residual Inflammation Detected via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose Tapering of Adalimumab in Clinical Remission Rheumatoid ArThrits (RA) Subjects (PREDICTRA)	Number Agreed	1	1	Date Agreed	03/02/2017	0	03/02/2017	0	Recruitment Finished	
26312	15/SC/0409	183061	Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration	Range Agreed	5	10	Date Agreed	17/03/2017	6	17/03/2017	6	Recruitment Finished	
26313	15/LO/1598	178793	A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBOCONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF TOCILIZUMAB VERSUS PLACEBO IN PATIENTS WITH SYSTEMIC SCLEROSIS	Number Agreed	2	2	Date Agreed	31/01/2017	0	31/01/2017	0	Recruitment Finished	1 patient consented but failed randomisation
26314	15/EE/0391	189145	Golimumab: A UK Two-part Observational Study of its Utilisation and Impact in Patients with Ankylosing Spondylitis	Range Agreed	15	19	Date Agreed	01/04/2017	19	01/04/2017	19	Recruitment Finished	
26315	16/EE/0011	194393	A PROSPECTIVE, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 EFFICACY AND SAFETY STUDY OF OTO-104 GIVEN AS A SINGLE INTRATYMPANIC INJECTION IN SUBJECTS WITH UNILATERAL MENIERE'S DISEASE	Range Agreed	1	3	Date Agreed	15/09/2017	3	17/08/2017	3	Recruitment Finished	
26316	13/EM/0404	126102	A multicentre, prospective, randomized, open label study to assess the effect of serelaxin versus standard of care in acute heart failure (AHF) patients	Number Agreed	3	3	Date Agreed	31/07/2017	1	22/03/2017	1	Withdrawn By Sponsor	Trial closed early by Sponsor
26317	16/EE/0243	207331	A 6-MONTH, MULTICENTER, PHASE 3, OPEN-LABEL EXTENSION SAFETY STUDY OF OTO-104 GIVEN AT 3-MONTH	Range Agreed	1	3	Date Agreed	23/12/2017	1	15/09/2017	1	Withdrawn By Sponsor	trial closed early by Sponsor
26318	16/LO/1312	188434	A Phase 2, Randomised, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients with Dermatomyositis	Number Agreed	3	3	Date Agreed	30/06/2017	0	30/06/2017	0	Recruitment Finished	Very Rare Disease Area
26653	16/LO/1529	204206	Productivity losses and indirect costs after cardiovascular events in Europe	Number Agreed	11	22	Date Agreed	30/11/2017	4	30/11/2017	4	Recruitment Finished	